At the last check on Friday, Inozyme Pharma Inc.’s (NASDAQ:INZY) stock was up $0.37, moving up 7.71 percent to $5.15. The average number of shares traded per day over the past five days has been 557,406 shares. 3 times new highs have been achieved over the past 5 days, with a $0.10 gain in that time frame. In the last twenty days, the average volume was 683,301, while in the previous 50 days, it was 609,461.
Since last month, INZY stock retreated -1.18%. Shares of the company fell to $4.68 on 08/02/23, the lowest level in the past month. A 52-week high of $7.33 was reached on 07/21/23 after having rallying from a 52-week low of $0.99. Since the beginning of this year, INZY’s stock price has risen by 390.33% or $3.96, and marked a new high 20 times. However, the stock has declined by -29.76% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
INZY stock investors should be aware that Inozyme Pharma Inc. (INZY) stock had its last reported insider trading activity 3 days ago on Aug 01. Hopfner Robert Lorne, the Director of the company, purchased of 833,333 shares for $4.80 on Aug 01. It resulted in a $3,999,998 investment by the insider. Pivotal bioVenture Partners Fu added 833,333 shares at an average price of $4.80 on Aug 01. The insider now owns 2,923,110 shares following the transaction. On May 12, Director Hopfner Robert Lorne bought 228,702 shares at $6.25 apiece. The transaction was valued at $1,429,388.
Financial Health
In the three months ended March 30, Inozyme Pharma Inc.’s quick ratio stood at 10.70, while its current ratio was 10.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.23, and the total debt-to-equity ratio was 0.23.
In Inozyme Pharma Inc.’s quarter-end financial report for March 30, it reported total debt of $24.22 million against cash and short-term investments of $81.91 million. While analysts expected Inozyme Pharma Inc. to report -$0.45 quarterly earnings, the actual figure was -$0.4 per share, beating the consensus estimate by 11.10%. The liabilities of Inozyme Pharma Inc. were 38.45 million at the end of its most recent quarter ended March 30, and its total debt was $26.66 million. The value of shareholders’ equity is $44.03 million.
Technical Picture
This quick technical analysis looks at Inozyme Pharma Inc.’s (INZY) price momentum. With a historical volatility rate of 79.64%, the RSI 9-day stood at 38.40% on 03 August.
With respect to its five-day moving average, the current Inozyme Pharma Inc. price is up by +2.11% percent or $0.10. At present, INZY shares trade -5.14% below its 20-day simple moving average and +72.71% percent above its 100-day simple moving average. However, the stock is currently trading approximately -23.88% below its SMA50 and +84.82% above its SMA200.
Stochastic coefficient K was 6.27% and Stochastic coefficient D was 7.16%, while ATR was 0.45. Given the Stochastic reading of 12.40% for the 14-day period, the RSI (14) reading has been calculated as 40.40%. As of today, the MACD Oscillator reading stands at -0.31, while the 14-day reading stands at -0.81.
Analyst Ratings
Jefferies upgraded its rating on Inozyme Pharma Inc. (NASDAQ: INZY) to a Buy in a note to investors on March 23, 2023. The analysts firm previously had a Hold rating on the stock.Inozyme Pharma Inc. (INZY) has been rated Buy by analysts. According to 0 brokerage firms, INZY is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Inozyme Pharma Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $17.50, the current consensus forecast for the stock is $13.00 – $40.00. Based on these forecasts, analysts predict Inozyme Pharma Inc. (INZY) will achieve an average price target of $21.00.
